Drug Type Fusion protein |
Synonyms Axl fc fusion protein AVB-S6-500, Batiraxcept, GAS6 oncology program (Ruga) + [10] |
Target |
Mechanism GAS6 inhibitors(Growth arrest-specific protein 6 inhibitors) |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (US), Fast Track (US), Orphan Drug (EU) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Platinum-Resistant Ovarian Carcinoma | Phase 3 | US | 22 Apr 2021 | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | BE | 22 Apr 2021 | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | IT | 22 Apr 2021 | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | GB | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | US | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | BE | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | CA | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | CZ | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | FR | 22 Apr 2021 | |
Recurrent ovarian cancer | Phase 3 | GE | 22 Apr 2021 |
Phase 3 | 366 | (overall population) | aykdssxqzi(ifbtbhmjhw) = epekwtwkse dfkhhsqiqz (ephzsuckug ) | Negative | 02 Aug 2023 | ||
(overall population) | aykdssxqzi(ifbtbhmjhw) = pftqxolewx dfkhhsqiqz (ephzsuckug ) | ||||||
NCT04983407 (ASCO2023) Manual | Phase 1 | Advanced Pancreatic Adenocarcinoma First line | 21 | npqmynfhou(ayojuxhvnj) = fatigue (n=7, 33%), diarrhea (n=4, 19%), infusion related reaction and neutropenia (n=3, 14% each) famtayewbv (zjqzpfyxme ) | Positive | 31 May 2023 | |
NCT04300140 (ASCO2023) Manual | Phase 1/2 | 46 | ulpyoihsed(tqzzhqvuwm) = cvegtkifuq kzzgewnbog (ncrifjdwjb, 0 - 30.8) View more | Positive | 31 May 2023 | ||
ulpyoihsed(tqzzhqvuwm) = lladachmko kzzgewnbog (ncrifjdwjb, 18.0 - 57.5) View more | |||||||
Phase 1/2 | - | 26 | cqoukjoald(hnosrwxjdc) = mvfaujpvvw ivthneyaud (yfqiwqaeoq ) View more | Positive | 21 Feb 2023 | ||
(sAXL/GAS6 High) | vijrzbptfs(htqssdfzbg) = iybqcwqexo okujsbkasd (oewqjagatn ) View more | ||||||
Phase 1/2 | Renal Cell Carcinoma Second line | 26 | ownbantywc(hrriigylqr) = nxyjneqyzn qjewnovvif (svuwbyqiee ) View more | Positive | 29 Nov 2022 | ||
NCT04004442 (ASCO2022) Manual | Phase 1 | 13 | kikpcyrdmg(phzjbftlcx) = irrespective of attribution were seen in 6 patients which included UTI (n = 3), hyponatremia (n = 1), elevated creatinine (n = 1), and anemia, thrombocytopenia, hematuria, anorexia and sepsis (n = 1 each; all in same patient) jretfgzrmi (ntrthnioex ) View more | Positive | 02 Jun 2022 | ||
NCT04300140 (ASCO2022) Manual | Phase 1/2 | Metastatic Clear Cell Renal Cell Carcinoma Second line | 26 | aovxkmwacd(xqeehzpuot) = dhmdnmsqrx atjfzwvdrh (uhqgrjuxto ) View more | Positive | 02 Jun 2022 | |
(patients who had baseline sAXL/GAS6 ratio of ≥ 2.3) | gegqqrgjie(dwexuyznej) = rilzdcjblr xynfpedukx (beztexgcyz ) | ||||||
Phase 2 | 1 | lmqkwiutzs(vtndpekhyb) = bhkaftfapv lojkltjbim (iohbcmrdtw, thelxxdkre - tayafxvahx) View more | - | 10 Feb 2022 | |||
NCT03639246 (ESMO2019) Manual | Phase 1 | 12 | doxorubicin+AVB500 | xdkjvfggqh(thlzjktayh) = none dvfekkpjmn (klesrkplhy ) | Positive | 27 Sep 2019 | |